Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial.

Dapagliflozin improved the eGFR slope from 2 weeks to 12 months versus placebo in 424 heart transplant recipients, with a between-group difference of 1.7 mL/min/1.73 m² (p=0.03).

• Why it matters: Kidney function often declines after heart transplantation, partly linked to calcineurin inhibitor exposure, and SGLT2 inhibitor evidence in this population remains limited.
• What they did: In a multicenter, double-blind, randomized, placebo-controlled trial at six Northern European centers, 430 adults (eGFR ≥25 mL/min/1.73 m², ≥1 year post-transplant) received dapagliflozin 10 mg daily or placebo.
• The result: From 2 weeks to 12 months, eGFR change was 2.0 (95% CI 1.0–3.1) with dapagliflozin and 0.3 (95% CI -0.8–1.4) with placebo, with no unexpected safety signals and similar adverse event rates.

AI summary of the abstract · may contain errors · not medical advice · read the paper.